Trial Profile
A retrospective study to compare the efficacy of everolimus and axitinib as a second-line therapy for the treatment of metastatic renal cell carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2016
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Apr 2016 New trial record